Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis

References

• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
   PubMed Web of Science ®Google Scholar
• National Psoriasis Foundation. 2009. Available at: http://www.psoriasis.org
   Google Scholar
• Gladman DD. Psoriatic arthritis. Dermatol Ther 2009;22:40-55
   PubMed Web of Science ®Google Scholar
• Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531-7
   PubMed Web of Science ®Google Scholar
• Cohen AD, Sherf M, Vidavsky L, et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008;216:152-5
   Google Scholar
• Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004;51:704-8
   PubMed Web of Science ®Google Scholar
• Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-84
   PubMed Web of Science ®Google Scholar
• Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003;17:257-70
   PubMed Web of Science ®Google Scholar
• Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med 1996;334:1717-25
   PubMed Web of Science ®Google Scholar
• Schottelius AJ, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-alpha – implications for psoriasis. Exp Dermatol 2004;13:193-222
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol 2003;2:375-7
   PubMedGoogle Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12
   PubMed Web of Science ®Google Scholar
• Hohmann HP, Remy R, Brockhaus M, et al. Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem 1989;264:14927-34
   PubMed Web of Science ®Google Scholar
• Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989;42:270-5
   PubMed Web of Science ®Google Scholar
• Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor alpha. J Exp Med 1988;167:1511-16
   PubMed Web of Science ®Google Scholar
• Lantz M, Gullberg U, Nilsson E, et al. Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J Clin Invest 1990;86:1396-402
   Google Scholar
• Engelmann H, Aderka D, Rubinstein M, et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989;264:11974-80
   PubMed Web of Science ®Google Scholar
• Ythier A, Gascon MP, Juillard P, et al. Protective effect of natural TNF-binding protein on human TNF-induced toxicity in mice. Cytokine 1993;5:459-62
   PubMed Web of Science ®Google Scholar
• Lou J, Ythier A, Burger D, et al. Modulation of soluble and membrane-bound TNF-induced phenotypic and functional changes of human brain microvascular endothelial cells by recombinant TNF binding protein I. J Neuroimmunol 1997;77:107-15
   PubMed Web of Science ®Google Scholar
• Porat R, Paddock HN, Schwaitzberg SD, et al. Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis. Crit Care Med 1995;23:1080-9
   PubMed Web of Science ®Google Scholar
• Trinchard-Lugan I, Ho-Nguyen Q, Bilham WM, et al. Safety, pharmacokinetics and pharmacodynamics of recombinant human tumour necrosis factor-binding protein-1 (onercept) injected by intravenous, intramuscular and subcutaneous routes into healthy volunteers. Eur Cytokine Netw 2001;12:391-8
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Lemmens L, van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003;17:185-92
   PubMed Web of Science ®Google Scholar
• Glatt S, Fuseau E, Buraglio M, et al. Population pharmacokinetics of onercept in healthy subjects. Clin Pharmacokinet 2005;44:1295-304
   PubMed Web of Science ®Google Scholar
• Sattar N, Crompton P, Cherry L, et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007;56:831-9
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Humira Summary of Product Characteristics (SPC). 2009. Available at: http://emc.medicines.org.uk/document.aspx?documentId=21201 [Last accessed 29 October 2009]
   Google Scholar
• European Medicines Agency. Enbrel Summary of Product Characteristics (SPC). 2009. Available at: http://emc.medicines.org.uk/medicine/19161/SPC/Enbrel+25mg+solution+for+injection+in+pre-filled+syringe/ [Last accessed 21 October 2009]
   Google Scholar
• European Medicines Agency. Remicade Summary of Product Characteristics (SPC). 2009. Available at: http://emc.medicines.org.uk/medicine/3236/SPC/Remicade+100mg+powder+for+concentrate+for+solution+for+infusion/ [Last accessed 21 October 2009]
   Google Scholar
• Colombel JF, Loftus EVJ, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31
   PubMed Web of Science ®Google Scholar
• Goode S, Tierney G, Deighton C. Life threatening intra-abdominal sepsis in patients on anti-TNF-alpha therapy. Gut 2006;55:590-1
   PubMed Web of Science ®Google Scholar
• Kling A, Mjorndal T, Rantapaa-Dahlqvist S. Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNFalpha antagonists. J Clin Rheumatol 2004;10:119-22
   PubMed Web of Science ®Google Scholar
• Sanchez Carazo JL, Mahiques SL, Oliver MV Safety of etanercept in psoriasis: a critical review. Drug Saf 2006;29:675-85
   PubMed Web of Science ®Google Scholar
• Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007;11:R49
   PubMed Web of Science ®Google Scholar
• Remick DG, Bolgos G, Copeland S, et al. Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 2005;73:2751-7
   PubMed Web of Science ®Google Scholar
• Damas P, Ledoux D, Nys M, et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992;215:356-62
   PubMed Web of Science ®Google Scholar
• Matsuda N, Hattori Y. Systemic inflammatory response syndrome (SIRS): molecular pathophysiology and gene therapy. J Pharmacol Sci 2006;101:189-98
   PubMed Web of Science ®Google Scholar
• Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55
   Google Scholar
• Matsumoto S, Hidaka S, Goto K, et al. Sivelestat treatment for acute respiratory distress syndrome in an infant. J Anesth 2009;23:288-91
   PubMed Web of Science ®Google Scholar
• American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74
   Google Scholar
• Marino P. The ICU Book. Baltimore: Williams & Wilkins, 1998
   Google Scholar
• Rippe J, Irwin R, Cerra FB. Irwin and Rippe's Intensive Care Medicine. Philadelphia: Lippincott-Raven, 1999
   Google Scholar
• Singh VK, Wu BU, Bollen TL, et al. Early systemic inflammatory response syndrome is associated with severe acute pancreatitis. Clin Gastroenterol Hepatol 2009;7:1247-51
   PubMed Web of Science ®Google Scholar
• Kettelhack C, Hohenberger P, Schulze G, et al. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med 2000;28:1040-6
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:888-93
   PubMed Web of Science ®Google Scholar
• Hunfeld KP, Bingold T, Brade V, et al. Molecular biological detection of pathogens in patients with sepsis. Potentials, limitations and perspectives [in French]. Anaesthesist 2008;57:326-37
   Google Scholar